AACR 2025 (poster): Clinical response to immune checkpoint inhibitors in melanoma is associated with distinct gut bacterial species that promote anti-tumour immunity by different mechanisms.
https://microbiotica.com/wp-content/uploads/2024/06/Microbiotica_Logo_RGB.svg00immunocityhttps://microbiotica.com/wp-content/uploads/2024/06/Microbiotica_Logo_RGB.svgimmunocity2025-04-29 09:00:302025-04-29 09:00:49AACR 2025 (poster): Clinical response to immune checkpoint inhibitors in melanoma is associated with distinct gut bacterial species that promote anti-tumour immunity by different mechanisms.
